Medindia

X

WaferGen Signs Exclusive Distribution Agreements for SmartSlide(TM) Micro-Incubation System in Switzerland, Taiwan and the Nordic Region

Monday, July 28, 2008 General News J E 4
Advertisement
FREMONT, Calif., July 28 WaferGen Biosystems,Inc. (OTC Bulletin Board: WGBS), a leading developer of state-of-the-art geneexpression, genotyping, cell biology and stem cell research systems, todayannounced the signing of exclusive distribution agreements for the company'sSmartSlide(TM) Micro-Incubation System with Bucher Biotec AG in Switzerland,Unimed Healthcare Inc. in Taiwan and AH diagnostics AS in the Nordic region(Denmark, Sweden, Norway and Finland). The distributor agreements coverWaferGen's entire family of SmartSlide Micro-Incubation System products.Bucher Biotec, Unimed Healthcare and AH diagnostics are each leadingdistributors of innovative products and services to cell biologists and stemcell researchers in the life science markets within their geographic areas offocus.

WaferGen's SmartSlide Micro-Incubation System is a first-of-its-kindfamily of integrated fluidics exchange micro-incubation products that workseamlessly with inverted microscopes. This breakthrough technology is enablingcell biology and stem cell researchers to conduct complex time lapse imagingstudies to characterize, differentiate and proliferate cells, as well as growstem, primary and other difficult to cultivate cells in consistently optimalphysiological conditions. These innovative capabilities will allow researchersto pursue cutting-edge research topics that are not addressable with existingtechnology. For example, the SmartSlide 200 Micro-Incubation System allowsresearchers to precisely control and vary oxygen, carbon dioxide and nitrogenparameters in order to create anoxia and hypoxia conditions which are criticalfor growth and differentiation of stem cells.

"These key distributor agreements represent yet another importantmilestone in our strategic efforts to expand the reach of our SmartSlideMicro-Incubation System into new key foreign markets," stated Alnoor Shivji,WaferGen's chairman and chief executive officer. "This innovative platform isalready providing critical performance advantages to researchers in severalvaluable international markets through our existing distributor agreements inGermany, France, the United Kingdom, Australia, Singapore and the Benelux. Inkeeping with this strategy, we expect to continue to build our SmartSlideMicro-Incubation System customer base with additional internationaldistributor agreements this year."

About the SmartSlide(TM) Micro-Incubation System

WaferGen has developed and is currently marketing the SmartSlide Micro-Incubation System, a first-of-its-kind family of integrated fluidics exchangemicro-incubation products that work seamlessly with inverted microscopes. Thisbreakthrough technology is enabling cell biology and stem cell researchers toconduct complex time lapse imaging studies to characterize, differentiate andproliferate cells, as well as grow stem, primary and other difficult tocultivate cells in consistently optimal physiological conditions. Theseinnovative capabilities will allow researchers to pursue cutting-edge researchtopics that are not addressable with existing technology. For example, theSmartSlide 200 Micro-Incubation System allows researchers to precisely controland vary oxygen, carbon dioxide and nitrogen parameters in order to createanoxia and hypoxia conditions which are critical for growth anddifferentiation of stem cells.

The core element of the SmartSlide Micro-Incubation System is the compact,sterile and disposable SmartSlide-6 Micro-Incubator which is designed tomaintain cells at specific physiological conditions for prolonged cell ortissue imaging. The SmartSlide-6 Micro-Incubator allows for programmablefluidics exchanging, enabling the delivery of up to six nutrient media and gasinto each of its six individual wells in both intermittent and continuousperfusion modes.

WaferGen has developed a family of SmartSlide Micro-Incubation Systemproducts built upon the
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Nventa Announces Final Data from HspE7 Phase 1 Cer...
S
Exforge(R) Helps Nearly Twice as Many Patients Con...